Biogen's Alzheimer's drug Leqembi, fully approved by the FDA seven months ago, has only 2,000 patients currently taking the medicine in the US. An additional 3,800 patients have signed up for the treatment, indicating rising demand for the drug.
7News is shedding light on an issue that impacts thousands of people: a lack of diversity in clinical trials for medicines and treatments for Alzheimer's disease. https://t.co/XYggBM21hn
2000 patients in 7 months in US. The capacity of those few lecanemab advocates actually prepared and able to give the drug and the uncertain risk:benefit presented to patients by those without CoIs will limit the market to a small niche. Most will wait for effective treatments. https://t.co/b1kC09bYnM
Seven months after the FDA fully approved a Biogen treatment for Alzheimer’s disease, only about 2,000 patients are taking Leqembi nationwide. https://t.co/2GJ8mH4cbU
Biogen is seeing rising demand for the Alzheimer's drug Leqembi, with the company estimating that 3,800 patients prescribed or close to being prescribed the treatment as of last week. https://t.co/f4EV7WSCHV
While just 2,000 Alzheimer's patients are currently taking Leqembi, an additional 3,800 patients have signed up to receive the drug. https://t.co/aw613ARrVg
Seven months after US drug regulators fully approved Biogen’s treatment for Alzheimer’s disease, only about 2,000 patients are taking the medicine nationwide, the company said Tuesday. https://t.co/ZRDbSHKpsa